IL2 and synovial sarcoma: The first evidence came from Marzec M. et al. [46], who demonstrated that IL-2 triggered this pathway in activated primary SS cells and that its inhibition, obtained via treatment with the mTORC1 inhibitor rapamycin [46,47], was able to block SS cell growth in vitro [46] as well in a xenograft T-cell lymphoma mouse model [48].